TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis

Lu Miao; Li Jing; Buze Chen; Tian Zeng; Youguo Chen

doi:10.2174/0115665240260252230919054858

TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis

Curr Mol Med. 2023 Oct 16. doi: 10.2174/0115665240260252230919054858. Online ahead of print.

Authors

Lu Miao^{1

2}, Li Jing², Buze Chen², Tian Zeng², Youguo Chen¹

Affiliations

¹ Department of Gynecology, The First Affiliated Hospital of Soochow University, Suzhou 215026, China.
² Department of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221009, China.

PMID: 38178662
DOI: 10.2174/0115665240260252230919054858

Abstract

Background: Some tumors have a poor prognosis regarding TPD52 (tumor protein D52). This study aims to explore TPD52's role in the cancer process from a pan-cancer perspective.

Methods: A pan-cancer analysis was conducted to investigate how TPD52 may be involved in cancer as well as its association with prognosis.

Results: A variety of human cancers express TPD52 abnormally and correlate with clinical stage. There was a significant association between low expression of TPD52 and poor survival in BRCA, KIRP, LAML, LIHC, UCEC, and UVM. TPD52 alterations were most frequently amplified in pan-cancer. The co-occurrence of 10 genes alterations was found in the TPD52 altered group. There was a significant association between TPD52 expression and MSI in four cancer types and TMB in twelve cancer types. There was a significant correlation between TPD52 expression and immunerelated cell infiltration. A significant correlation was found between TPD52 expression in many tumor types and 8 immune checkpoint genes. There were signaling pathways involved in pan-cancer caused by TPD52, including endocytosis, Fc gamma Rmediated phagocytosis, and so on. TPD52 may be involved in chemotherapy and chemoresistance.

Conclusion: The TPD52 gene may be important for human cancer treatment.

Keywords: Pan cáncer; TPD52; drug sensitivity; genomic alteration.; immune infiltration; prognosis.